| 106.78 -2 (-1.84%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 126.31 |
1-year : | 131.32 |
| Resists | First : | 108.14 |
Second : | 112.44 |
| Pivot price | 108.57  |
|||
| Supports | First : | 101.19 |
Second : | 84.19 |
| MAs | MA(5) : | 108.86 |
MA(20) : | 107.31 |
| MA(100) : | 103.94 |
MA(250) : | 98.1 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 55.8 |
D(3) : | 66.5 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 112.44 | Low : | 80.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PPH ] has closed above bottom band by 27.7%. Bollinger Bands are 20% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 108.3 - 109.34 | 109.34 - 109.97 |
| Low: | 104.32 - 105.71 | 105.71 - 106.55 |
| Close: | 105.21 - 107.44 | 107.44 - 108.79 |
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Mon, 13 Jul 2026
PPH ETF Profile: Dividends, Returns (NASDAQ:PPH) - TradingView
Fri, 10 Jul 2026
VanEck Pharmaceutical ETF (PPH) Stock Price | Quotes & News - Moomoo
Thu, 09 Jul 2026
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? - The Motley Fool
Wed, 08 Jul 2026
4 ETF Winners of June Likely to Gain in July - TradingView
Sun, 05 Jul 2026
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? - AOL.com
Sat, 04 Jul 2026
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|